Using 3D-Clustered Cells to Improve Immune Tolerance in Transplant Patients
Injectable 3D-Clustered Human Fibroblastic Reticular Cells for Expanding Regulatory T Cells
This study is exploring a new way to help transplanted organs be accepted by the body by using special cells that support the immune system, which could lead to better outcomes for people receiving organ transplants.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Duquesne University NIH-funded |
| Lab location | 1 site (Pittsburgh, United States) |
| Project ID | NIH-11138215 on NIH RePORTER |
What this research studies
This research investigates a novel approach to enhance the immune tolerance of transplanted organs by using injectable 3D-clustered human fibroblastic reticular cells (FRCs). These cells are designed to support the expansion of regulatory T cells (Tregs), which play a crucial role in preventing organ rejection. The study aims to develop a method that allows for the effective delivery of these cells into the body, potentially improving the outcomes for transplant recipients. By creating a 3D environment for the FRCs, the researchers hope to maintain their beneficial properties and enhance their effectiveness in promoting Treg-mediated tolerance.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who are undergoing or have undergone organ transplantation and are at risk of organ rejection.
Not a fit: Patients who are not candidates for organ transplantation or those who have not experienced transplant rejection may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved transplant outcomes and a better quality of life for organ recipients by reducing the need for lifelong immunosuppressive therapy.
How similar studies have performed: While some studies have shown promise in using Tregs for transplant tolerance, the specific approach of using 3D-clustered FRCs is relatively novel and has not been extensively tested in clinical settings.
Where this research is happening
Pittsburgh, United States
- Duquesne University — Pittsburgh, United States (Active)
Researchers
- Principal investigator: Meng, Wilson S — Duquesne University
- Study coordinator: Meng, Wilson S
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.